Overview

Prophylactic Human Vaccines Market Overview:

Prophylactic human vaccinations enhance the immune response and are meant to reduce the consequences of future pathogen infection in humans. Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) vaccines are being developed using novel vaccine development methods such as viral-like particles. CureVac AG, for example, earned a EUR 2 million Vaccination Prize from the European Commission for their unique RNActive vaccine technology. This RNActive vaccine technology enables the manufacturing of safe, effective, and cost-efficient vaccinations that are resistant to high temperatures as well as accidental freezing.
During the projected period, the prophylactic human vaccine market is likely to rise due to an increase in pipeline research and increased engagement of major companies in vaccine development. CureVac AG, for example, stated in October 2018 that it will begin a dosage escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a preventive vaccination that contains the rabies virus glycoprotein RABV-G. This allows vaccinated individuals' own cells to manufacture RABV-G protein, triggering an immunological response. The investigation is expected to be completed. Furthermore, increased endeavours by various scientists to discover creative ways to combat infectious illnesses are likely to propel market expansion. In September 2018, VBI Vaccines Inc. announced the creation of three Scientific and Clinical Advisory Boards (SABs) comprised of prominent specialists in infectious disease and immuno-oncology research and vaccine development targeting hepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). Because of improved vaccine development, this partnership is projected to fuel market expansion. Significant vaccine development challenges, such as viral variety and a scarcity of animal models, are expected to stymie the expansion of the preventive human vaccination industry. According to Gastroenterology in October 2018, vaccine development demands a large investment from a variety of resources and is quite difficult. Designing human vaccination trials is difficult since the risks of developing an acute illness after inoculation are relatively high. As a result, anti-viral medication must be provided quickly, making illness management difficult.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Prophylactic Human Vaccines Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Prophylactic Human Vaccines Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Prophylactic Human Vaccines Market:
• GlaxoSmithKline Plc.
• Merck and Co., Inc.
• Pfizer, Inc.
• Janssen Pharmaceuticals, Inc.
• Altimmune, Inc.
• Bharat Biotech Limited
• Serum Institute of India, Pvt. Ltd
• Sanofi Pasteur SA
• Shanghai BravoBio Co., Ltd.
• SK Chemicals Co., Ltd.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Prophylactic Human Vaccines Market Segmentation:          
By Vaccine Technology
• Live Attenuated vaccine
• Inactivated Vaccines
• Toxoid Vaccines
• Polysaccharide Vaccines
• Conjugate Vaccines
• Recombinant Vaccines

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Prophylactic Human Vaccines Market By Vaccine Technology and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1. Objectives of the Study
  1.2. Market Definition
  1.3. Market Scope
       1.3.1. Years Considered for the Study
       1.3.2. Market Covered
  1.4. Currency
  1.5. Limitations
  1.6. Stakeholders

2. Research Methodology
  2.1. Research Data
       2.1.1. Secondary Data
              2.1.1.1. Key Data from Secondary Sources
       2.1.2. Primary Data
              2.1.2.1. Key Data from Primary Sources
  2.2. Market Size Estimation
  2.3. Market Breakdown and Data Triangulation
  2.4. Assumptions for the Study  

3. Executive Summary
  3.1. Market Outlook
  3.2. Segment Outlook
  3.3. Competitive Insights

4. Prophylactic Human Vaccines Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Prophylactic Human Vaccines Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Prophylactic Human Vaccines Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Prophylactic Human Vaccines Market, By Vaccine Technology Historical Analysis and Forecast 2022-2028 (USD Million)  
  7.1. Live Attenuated vaccine
  7.2. Inactivated Vaccines
  7.3. Toxoid Vaccines
  7.4. Polysaccharide Vaccines
  7.5. Conjugate Vaccines
  7.6. Recombinant Vaccines

8. North America Prophylactic Human Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
  8.1. Introduction
  8.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       8.2.1. U.S.A
       8.2.2. Canada
       8.2.3. Mexico
  8.3. Market Size (USD Million) Forecast for North America 2022-2028

9. Latin America Prophylactic Human Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   9.1. Introduction
   9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        9.2.1. Brazil
        9.2.2. Venezuela
        9.2.3. Argentina
        9.2.4. Rest of Latin America
   9.3. Market Size (USD Million) Forecast for Latin America 2022-2028

10. Europe Prophylactic Human Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         10.2.1. Germany
         10.2.2. U.K        
         10.2.3. France
         10.2.4. Italy
         10.2.5. Spain
         10.2.6. Russia
         10.2.7. Poland
         10.2.7. Rest of Europe
   10.3. Market Size (USD Million) Forecast for Europe 2022-2028

11. Asia Pacific Prophylactic Human Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         11.2.1. Japan
         11.2.2. China
         11.2.3. India
         11.2.4. Australia and New Zealand
         11.2.5. ASEAN
         11.2.6. Rest of Asia Pacific
   11.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

12. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. GCC
         12.2.2. Israel
         12.2.3. South Africa
         12.2.4. Rest of MEA
   12.3. Market Size (USD Million) Forecast for MEA 2022-2028

13. Market Share Analysis and Competitive Landscape  
   13.1. Global Landscape - Key Players, Revenue and Presence
   13.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   13.3. Global Emerging Companies
   13.4. North America - Market Share Analysis and Key Regional Players
   13.5. Europe - Market Share Analysis and Key Regional Players
   13.6. Asia Pacific - Market Share Analysis and Key Regional Players
   13.7. Global Key Player - Growth Matrix

14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   14.1. GlaxoSmithKline Plc.
         14.1.1. Company Overview
         14.1.2. Product Portfolio
         14.1.3. SWOT Analysis
         14.1.4. Financial Overview
         14.1.5. Strategic Overview
   14.2. Merck and Co., Inc.
         14.2.1. Company Overview
         14.2.2. Product Portfolio
         14.2.3. SWOT Analysis
         14.2.4. Financial Overview
         14.2.5. Strategic Overview
   14.3. Pfizer, Inc.
         14.3.1. Company Overview
         14.3.2. Product Portfolio
         14.3.3. SWOT Analysis
         14.3.4. Financial Overview
         14.3.5. Strategic Overview
   14.4. Janssen Pharmaceuticals, Inc.
         14.4.1. Company Overview
         14.4.2. Product Portfolio
         14.4.3. SWOT Analysis
         14.4.4. Financial Overview
         14.4.5. Strategic Overview
   14.5. Altimmune, Inc.
         14.5.1. Company Overview
         14.5.2. Product Portfolio
         14.5.3. SWOT Analysis
         14.5.4. Financial Overview
         14.5.5. Strategic Overview          
   14.6. Bharat Biotech Limited
         14.6.1. Company Overview
         14.6.2. Product Portfolio
         14.6.3. SWOT Analysis
         14.6.4. Financial Overview
         14.6.5. Strategic Overview      
   14.7. Serum Institute of India, Pvt. Ltd
         14.7.1. Company Overview
         14.7.2. Product Portfolio
         14.7.3. SWOT Analysis
         14.7.4. Financial Overview
         14.7.5. Strategic Overview
   14.8. Sanofi Pasteur SA
         14.8.1. Company Overview
         14.8.2. Product Portfolio
         14.8.3. SWOT Analysis
         14.8.4. Financial Overview
         14.8.5. Strategic Overview
   14.9. Shanghai BravoBio Co., Ltd.
         14.9.1. Company Overview
         14.9.2. Product Portfolio
         14.9.3. SWOT Analysis
         14.9.4. Financial Overview
         14.9.5. Strategic Overview
   14.10.SK Chemicals Co., Ltd.
         14.10.1. Company Overview
         14.10.2. Product Portfolio
         14.10.3. SWOT Analysis
         14.10.4. Financial Overview
         14.10.5. Strategic Overview
   
15. Pre and Post COVID-19 Impact
   15.1. Positive influence on the healthcare industry
   15.2. The financial disruption of the manufacturing sector
   15.3. Impact of COVID-19 on emerging companies
   15.4. Significant mandates in the healthcare regulations initiated by administrations
   15.5. The overall economic slowdown of the developing and developed nations

16. FutureWise SME Key Takeaway Points for Client

Tables

Figures